HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2002; **17**: 445–446.

Author Index

Agarwal, A. K., 91
Akagawa, Y., 191
Aksu, G., 357
Amore, M., 99
Asghar, S., 425
Asghar, S. J., 321
Atmaca, M., 401
Atti, M. D., 99
Azzoni, A., 61

Bahk, W.-M., 341
Begg, E. J., 187
Benkert, O., S23
Berardi, D., 99
Beraus, W., 353
Bergougnan, L., 1
Berk, M., 175, 407
Bianchetti, G., 1
Bourin, M., 239, 383
Bradwejn, J., 285
Buchanan, T., 309
Burian, S. E., 141

Canal, M., 1
Carretero, M., 419
Catalán, R., 419
Chae, J.-H., 341
Cho, M.-J., 279
Chong, S.-A., 305
Chul-Lee, 341
Cohen, A. F., 83
Colombel, M. C., 239
Conca, A., 353
Costa e Silva, J. A., 131
Crews, W. D., 267
Curran, H. V., 51
Curran, S., 75

Dadhich, A. P., 91
Dailly, E., 239
Dannon, P. N., 329, 349
De Ronchi, D., 99
Deswal, R. S., 91
Dieci, M., 253
Díaz-Ricart, M., 419
Dolberg, O. T., 349
Dörr, A., 213

Erermis, S., 357
Escolar, G., 419

Faltus, F., 299
Ferrari, G., 99
Fiorentini, V. A., 253
Frick, H. C., 103

Gastó, C., 419
Genel, F., 357
Gijsman, H. J., 83
Gómez-Gil, E., 419
Greville, W., 45
Grunberg, N. E., 361
Grunhaus, L., 329, 349
Gunnarsson, T., 285

Häfliger, T., 247
Hanstock, C. C., 321, 425
Harris, L., 75
Harrison, B. J., 293
Harvey, D., 103
Hascoët, M., 239
Hausmann, A., 353
Heffernan, T., 309
Hennig, J., 213
Henning, U., 15
Hessing, T. J., 83
Higuchi, H., 95, 195, 431
Hinterhuber, H., 353
Hirschfeld, R. M. A., S33
Hishikawa, Y., 191
Huak, C. Y., 305

Iancu, I., 329
Ibrahim, E. S. R., 225
Ichim, L., 175
Ito, K., 195
Itoh, M., 413

Jolliet, P., 239
Jun, T.-Y., 341

Kalra, R., 91
Kaltschmidt, M., 213
Kamata, M., 195
Kanazawa, I., 369
Kane, J., 305
Kang, B.-J., 279
Kano, M., 413
Keller, M. B., S43
Kennedy, D. O., 35
Kennedy, M. A., 187
Kim, K.-S., 341
Kim, M.-D., 279
Klein, L. C., 361
Klimke, A., 15
Knott, V. J., 285
König, P., 353
Kuloglu, M., 401
Kurup, P. A., 29
Kurup, R. K., 29
Kuschke, R. H., 175
Kutukculer, N., 357

Lambert, O., 383
Langosch, J. M., 115
Latour, C., 103
Lattimer, J. K., 103
Lee, S.-J., 279
Liguori, A., 141
Ling, J., 309
Linnet, K., 233
Lubin, G., 181
Lum, A., 305

Macdonald, A., 75
Mackay, M., 151
Maes, M., 175
Maher, B. F. G., 163
Mahoney, C., 285
Malhi, G. S., 407
Masuda, Y., 191
Mauri, M. C., 253
Mbaya, P., 335
Mix, J. A., 267
Mochizuki, H., 413
Mrazek, L., 45
Muller, M., S23
Mythily, 305

Naito, S., 195
Nahas, G. G., 103
Nathan, P. J., 45, 163, 293
Natu, M. V., 91
Nemeroff, C. B., S13
Netter, P., 213

Copyright © 2002 John Wiley & Sons, Ltd.

Nishikawa, T., 197
Nishioka, S., 197
Nordin, C., 345
Norman, T. R., 293
Novotny, V., 299
Nutt, D. J., S37

Oades, R. D., 15
O'Connor, R. J., 361
O'Donnell, T., 321, 425
Okamura, N., 413
Olver, J. S., 293
Ozturk, C., 357

Pae, C.-U., 341
Parrott, A. C., 309
Patat, A., 1
Pauli, J. D., 353
Pennings, E. J. M., 83
Peschina, W., 353
Pieters, M. S. M., 83
Pittrow, D., S1
Pohl, A., 345
Polak, D., 349
Pollock, C., 75
Pompéia, S., 51

Quinche, P., 247

Raja, M., 61
Rao, M. L., 15
Reuter, M., 213
Ricketts, E., 45
Righini, A., 253
Roberts, R., 187
Robinson, J. H., 141
Rodgers, J., 309
Rogausch, A., 213
Roney, G., 75
Rosenzweig, P., 1
Rusted, J. M., 51

Sakurai, Y., 369
Salamero, M., 419
Sander, P., 213
Sato, K., 195
Schatzberg, A. F., S17
Schneider, H., 353
Schoemaker, R. C., 83
Scholey, A. B., 35, 151, 309
Shelmerdine, A., 163
Shimizu, T., 95, 195, 431
Shlik, J., 285
Shmushkevitz, M., 181
Silkstone, D., 75
Silverstone, P. H., 321, 425
Stedman, C. A. M., 187
Stigler, M., 247
Stine, M. M., 361
Stough, C., 45, 157, 163
Sugita, T., 95
Szegedi, A., S23

Tagawa, M., 413
Takahashi, H., 95, 195, 431
Tashiro, M., 413
Tezcan, E., 401
Thompson, C., S27
Thompson, J. C., 157
Tiplady, B., 151
Trimble, M. R., 115
Tsoh, J., 341
Tsukamoto, K., 195

Ulrich, M., 321, 425
Unal, A., 401

Valevski, A., 181
van Gerven, J. M. A., 83
Verkes, R. J., 83
Vita, A., 253
Volonter, L. S., 253

Wadee, A. A., 175
Watanabe, T., 413
Weizman, A., 181
Wesnes, K., 45, 163
Wilby, G., 157
Wilkinson, T. J., 187
Wittchen, H.-U., S1
Wood, L. A., 175
Wu, R. H., 321

Yanai, K., 413
Yatko, B. R., 361
Yoshida, K., 195, 431

Zieleniuk, I., 1
Zullino, D. F., 247

Copyright © 2002 John Wiley & Sons, Ltd.

HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2002; **17**: 447–448.

Keyword Index

acupuncture, 345
acute, 45
acute mania, 175
aggression, 247
alcohol, 141, 151
amisulpride, 1
antagonism, 151
anticholinergic, 51
antidepressants, 279, 383, S13, S17, S23, S27, S37, S43
antihistamines, 413
antipsychotic agents, 247
antipsychotic therapy, 61
antipsychotics, 75
anxiety, 181, 239
assessment, 91
attention deficit hyperactivity disorder, 225
atypical antipsychotics, 407

benzodiazepines, 383
bipolar disorder, 321, 407
brain, 103

caffeine, 151, 361
calcium channel blockers, 407
catatonia, 99
catecholamines, 293
CCK-4, 285
child behaviour checklist, 225
children and adolescents, 225
cholecystokinin, 285
chronic giardiasis, 357
cigarette smoking, 369
citalopram, 401
clinical trail, 267
clozapine, 115, 253, 407
clustering, 51
cognition, 45
cognitive, 267
cognitive functions 369
cognitive load, 35
complement, 175
compliance with treatment opinion and attitude scale, 225
compliance, 225
cortisol, 213
cotinine, 369
craving, 213
CRF receptors, S13
CYP2D6, 187

daily consumption, 361
decision-making, 141
demand, 35
dementia, 191
depression symptoms, 191
depression, 309, 345, S1, S13, S17, S27, S33, S43
desmethyldiazepam, 239
dexamethasone, 213
dexfenfluramine, 83
dextro-amphetamine, 425
diabetes mellitus, 61
diazepam, 239
digoxin, 29
disorganization, 99
dopamine noradrenaline serotonin, 15
drug abuse, 131
drug misuse, 131

ecstasy, 83, 309
EEG, 83
efficacy, 335, 401, S23
elderly, 267, S33
electroacupuncture, 345
epilepsy, 115
ERPs, 285
event-related potentials, 285

fluoxetine, 187, 299
fluvoxamine, 95

GAD, 383
gametotoxicity, 103
genotype, 187
Ginkgo biloba extract, 267
Ginkgo biloba, 35, 45, 279
Ginseng, 35
glucocorticoid receptors, S13
glucuronidation, 233
guidelines, 75

healthy volunteers, 1
high and low frequency, 353
high dose venlafaxine, 335
human, 141
hyperglycemia, 305
hyponatraemia, 187

ideas of reference, 15
illicit drugs, 131
immune system, 293
immunoglobulins, 175
immunological changes, 175
impaired glucose metabolism, 305
impulsivity, 213
inositol, 321
inspection time, 157
interleukin-6, 293
international data, 131
in vitro, 233

Korea, 341

lithium, 29, 321
long-term treatment, S43

magnesium, 29
magnetic resonance spectroscopy, 321, 425
major depression, 299, 335, 349, 419
MDMA, 83, 309
memory, 45, 267, 309
mental disorder, 75
metabolism, 233
metyrapone, 213
mirtazapine, S17, S23, S27, S33, S37, S43, 341
moclobemide, 401
molecular pharmacokinetics, 103
mood, 293, 309
muscarinic antagonist, 51
myo-inositol, 425

Na^+-K^+ ATPase, 29
naltrexone, 181
neuroleptic malignant syndrome, 99
neuropeptide Y, 345
neuropsychiatric disorders, 357
neuropsychological, 267
nicotine, 157, 213, 369
noncompliance, 225
nootropic, 45
norepinephrine, 329
norfluoxetine, 187

OCD, 383
olanzapine, 233, 247, 407

Copyright © 2002 John Wiley & Sons, Ltd.

older human subjects, 45
omega-3 fatty acids, 407
onset of action, S17, S23, S27, S33
opioid system, 181
oxazepam, 239

panic, 285
panic disorder, 285, 329, 383
paranoid, 15
paroxetine, 187
performance, 361
personality disorders, 247
pharmacodynamics, 1, 83
pharmacokinetics, 1, 83, 239
pharmacology, S17, S37
phosphomonoesters, 321, 425
PKPD, 83
platelet aggregation, 419
polydipsia, 253
positron emission tomography and histamine, 413
post-traumatic stress disorder, 181
prevalence, S1
primary care, S1
premature apoptosis, 103
psychiatric inpatients, 91
psychomotor agitation, 99
psychomotor performance, 91
psychosis, 115
psychotic depression, S13
PTSD, 341, 383

quantal state, 29
quetiapine, 407
quinacrine, 357

reboxetine, 329
5-HT receptor function, 419
5-HT_{2T} receptor, 419
recognition, S1
repetitive transcranial magnetic stimulation, 353
response predictor, S23
right parietal cortex (BA 40), 413
risk factors, 99
risk-taking, 141
risperidone, 95, 407
rTMS, 349

saccadic eye movements, 83
safety, S37, 335
scopolamine, 51
schizophrenia, 15, 95, 115, 305
sedation, 413
seizures, 115
selective NRI, 329
selective serotonin reuptake inhibitors, 383
semantic memory, 51
senile patient, 191
serotonin, 83, 293, 419
sexual dysfunction, 279
side effect, 353
side-effect, 401
simulated driving, 141
social anxiety, 383
social dysfunction, 247
social phobia, 401
sodium valproate, 321
spatial cognition, 413
speed/accuracy trade-off, 151
SSRI, 329
SSRIs, S27
SSRI augmentation, 95
SSRI failure, S33
stimulation placement, 353
switches, 51

tandospirone, 191
tardive dyskinesia, 61, 305
teacher report from scale, 225
testis, 103
THC, 103
thought-disorder, 15
tianeptine, 299
time estimation, 361
time perception, 361
tolerability, 1, S37, 335
transcranial magenetic stimulation, 349
transdermal patches, 157
transmutation, 29
treatment failure, 329
treatment resistance, 95
treatment resistant, 335
treatment, S1
tryptophan depletion, 293

verbal fluency, 51
visual analog scales, 349

Copyright © 2002 John Wiley & Sons, Ltd.

CONTENTS

Volume 17 Issue Nos 1–8 and Supplement 1

HUMAN PSYCHOPHARMACOLOGY

Issue No.1 January 2002

Review

A Review of the Pharmacokinetics, Tolerability and Pharmacodynamics of Amisulpride in Healthy Volunteers: **P. Rosenzweig, M. Canal, A. Patat, L. Bergougnan, I. Zieleniuk and G. Bianchetti** 1

Research Articles

Relations of Clinical Features, Subgroups and Medication to Serum Monoamines in Schizophrenia: **R. D. Oades, A. Klimke, U. Henning and M. L. Rao** 15

Detection of Endogenous Lithium in Neuropsychiatric Disorders – a Model for Biological Transmutation: **R. K. Kurup and P. A. Kurup** 29

Acute, Dose-dependent Cognitive Effects of *Ginkgo biloba*, *Panax ginseng* and their Combination in Healthy Young Volunteers: Differential Interactions with Cognitive Demand: **A. B. Scholey and D. O. Kennedy** 35

The Acute Nootropic Effects of *Ginkgo biloba* in Healthy Older Human Subjects: A Preliminary Investigation: **P. J. Nathan, E. Ricketts, K. Wesnes, L. Mrazek, W. Greville and C. Stough** 45

Verbal Fluency Facilitated by the Cholinergic Blocker, Scopolamine: **S. Pompéia, J. M. Rusted and H. V. Curran** 51

Short Report

Diabetes is not a Risk Factor for Tardive Dyskinesia: A Retrospective Observational Study: **M. Raja and A. Azzoni** 61

Book Reviews 65

Current Awareness 69

Issue No.2 March 2002

Reviews

Antipsychotics in Clinical Practice: Guidelines for Safe and Effective Use: **S. Curran, L. Harris, A. Macdonald, C. Pollock, G. Roney and D. Silkstone** 75

Pharmacokinetics of THC in Brain and Testis, Male Gametotoxicity and Premature Apoptosis of Spermatozoa: **G. G. Nahas, H. C. Frick, J. K. Lattimer, C. Latour and D. Harvey** 103

Research Articles

Saccadic Peak Velocity and EEG as End-points for a Serotonergic Challenge Test: **H. J. Gijsman, J. M. A. van Gerven, R. J. Verkes, R. C. Schoemaker, M. S. M. Pieters, E. J. M. Pennings, T. J. Hessing and A. F. Cohen** 83

Fluvoxamine Augmentation in Risperidone-resistant Schizophrenia: An open trial: **H. Takahashi, T. Sugita, H. Higuchi and T. Shimizu** 95

Clinical Risk Factors for Neuroleptic Malignant Syndrome: **D. Berardi, M. Dell'Atti, M. Amore, D. De Ronchi and G. Ferrari** 99

Epilepsy, Psychosis and Clozapine: **J. M. Langosch and M. R. Trimble** 115

Short Report
Psychomotor Performance of Psychiatric Inpatients Under Therapy: Assessment by Paper and Pencil Tests: **A. K. Agarwal, R. Kalra, M. V. Natu, A. P. Dadhich and R. S. Deswal** 91

Book Reviews 121

Current Awareness 123

Issue No.3 April 2002

Research Articles
Evidence-based Analysis of the Worldwide Abuse of Licit and Illicit Drugs: **J. A. Costa e Silva** 131

Effects of Alcohol on Risk-taking During Simulated Driving: **S. E. Burian, A. Liguori and J. H. Robinson** . 141

Interactions Between Alcohol and Caffeine in Relation to Psychomotor Speed and Accuracy: **M. Mackay, B. Tiplady and A. B. Scholey** 151

The Effects of Transdermal Nicotine on Inspection Time: **J. C. Thompson, G. Wilby and C. Stough** . . 157

Letter to the Editor
The Acute Effects of Combined Administration of *Ginkgo biloba* and *Bacopa Monniera* on Cognitive Function in Humans: **B. F. G. Maher, C. Stough, A. Shelmerdine, K. Wesnes and P. J. Nathan** . . . 163

Book Reviews 165

Current Awareness 169

Issue No.4 June 2002

Research Articles
Serological Observations in Patients Suffering from Acute Manic Episodes: **A. A. Wadee, R. H. Kuschke, L. A. Wood, M. Berk, L. Ichim and M. Maes** 175

Short-term Treatment of Post-traumatic Stress Disorder with Naltrexone: An Open-label Preliminary Study: **G. Lubin, A. Weizman, M. Shmushkevitz and A. Valevski** 181

Cytochrome P450 2D6 Genotype does not Predict SSRI (Fluoxetine and Paroxetine) Induced Hyponatraemia: **C. A. M. Stedman, E. J. Begg, M. A. Kennedy, R. Roberts and T. J. Wilkinson** 187

Effect of Serotonin 1A Agonist Tandospirone on Depression Symptoms in Senile Patients with Dementia: **Y. Masuda, Y. Akagawa and Y. Hishikawa** 191

Letters to the Editor
Remarkable Effect of Milnacipran in the Treatment of Japanese Major Depressive Patients: **H. Higuchi, K. Yoshida, H. Takahashi, S. Naito, K. Tsukamoto, M. Kamata, K. Ito, K. Sato and T. Shimizu** . . 195

A Case of Meige Dystonia Induced by Short-term Quetiapine Treatment: **T. Nishikawa and S. Nishioka** 197

Book Reviews 199

Current Awareness 201

Supplement No.1 June 2002

REDEFINING THE PHARMACOLOGICAL TREATMENT OF DEPRESSION – MIRTAZAPINE AND BEYOND

Guest Editor: R. Pinder
(Organon Inc., West Orange, New Jersey, USA)

Prevalence, Recognition and Management of Depression in Primary Care in Germany: The Depression 2000 Study: **H.-U. Wittchen and D. Pittrow** S1

New Directions in the Development of Antidepressants: The Interface of Neurobiology and Psychiatry: **C. B. Nemeroff** S13

Pharmacological Principles of Antidepressant Efficacy: **A. F. Schatzberg** S17

An Overview of the Clinical Efficacy of Mirtazapine: **O. Benkert, M. Muller and A. Szegedi** S23

Onset of Action of Antidepressants: Results of Different Analyses: **C. Thompson** S27

The Use of Mirtazapine in Difficult-to-Treat Patient Populations: **R. M. A. Hirschfeld** S33

Tolerability and Safety Aspects of Mirtazapine: **D. J. Nutt** S37

Rationale and Options for the Long-term Treatment of Depression: **M. B. Keller** S43

Supported by an educational grant from Organon

Issue No.5 July 2002

Research Articles

The Role of Cortisol Suppression on Craving for and Satisfaction from Nicotine in High and Low Impulsive Subjects: **M. Reuter, P. Netter, A. Rogausch, P. Sander, M. Kaltschmidt, A. Dörr and J. Hennig** 213

Rates of Adherence to Pharmacological Treatment among Children and Adolescents with Attention Deficit Hyperactivity Disorder: **E. S. R. Ibrahim** 225

Glucuronidation of Olanzapine by cDNA-expressed Human UDP-glucuronosyltransferases and Human Liver Microsomes: **K. Linnet** 233

Relationship between Cerebral Pharmacokinetics and Anxiolytic Activity of Diazepam and its Active Metabolites after a Single Intra-peritoneal Administration of Diazepam in Mice: **E. Dailly, M. Hascoët, M. C. Colombel, P. Jolliet and M. Bourin** 239

Olanzapine Improves Social Dysfunction in Cluster B Personality Disorder: **D. F. Zullino, P. Quiniche, T. Häfliger and M. Stigler** 247

Case Report

Efficacy of Clozapine in a Non-Schizophrenic Patient with Psychogenic Polydipsia and Central Pontine Myelinolysis: **M. C. Mauri, L. S. Volonteri, A. Fiorentini, M. Dieci, A. Righini and A. Vita** 253

Current Awareness 257

Issue No.6 August 2002

Research Articles

A Double-blind, Placebo-controlled, Randomized Trial of *Ginkgo Biloba* Extract EGb 761® in a Sample of Cognitively Intact Older Adults: Neuropsychological Findings: **J. A. Mix and W. D. Crews, Jr.** . . . 267

A Placebo-controlled, Double-blind Trial of *Ginkgo Biloba* for Antidepressant-induced Sexual Dysfunction: **B.-J. Kang, S.-J. Lee, M.-D. Kim and M.-J. Cho** . . . 279

Acute Cholecystokinin Effects on Event-related Potentials in Healthy Volunteers: **V. J. Knott, C. Mahoney, T. Gunnarsson, J. Bradwejn and J. Shlik** . . . 285

Effects of Serotonin and Catecholamine Depletion on Interleukin-6 Activation and Mood in Human Volunteers: **B. J. Harrison, J. S. Olver, T. R. Norman and P. J. Nathan** . . . 293

Tianeptine and Fluoxetine in Major Depression: a 6-week Randomised Double-blind Study: **V. Novotny and F. Faltus** . . . 299

Tardive Dyskinesia and Impaired Glucose Tolerance: **S.-A. Chong, Mythily, A. Lum, C. Y. Huak and J. Kane** . . . 305

Ecstasy/MDMA Attributed Problems Reported by Novice, Moderate and Heavy Recreational Users: **A. C. Parrott, T. Buchanan, A. B. Scholey, T. Heffernan, J. Ling and J. Rodgers** . . . 309

Book Reviews . . . 313

Current Awareness . . . 315

Issue No.7 October 2002

Research Articles

Chronic Treatment with Both Lithium and Sodium Valproate May Normalize Phosphoinositol Cycle Activity in Bipolar Patients: **P. H. Silverstone, R. H. Wu, T. O'Donnell, M. Ulrich, S. J. Asghar and C. C. Hanstock.** . . . 321

The Efficacy of Reboxetine in the Treatment-refractory Patients with Panic Disorder: An Open-label Study: **P. N. Dannon, I. Iancu and L. Grunhaus** . . . 329

Safety and Efficacy of High Dose of Venlafaxine XL in Treatment Resistant Major Depression: **P. Mbaya** . . . 335

Clinical and Biochemical Observations During Treatment of Depression with Electroacupuncture: A Pilot Study: **A. Pohl and C. Nordin** . . . 345

Monitoring the Response to rTMS in Depression with Visual Analog Scales: **L. Grunhaus, O. T. Dolberg, D. Polak and P. N. Dannon** . . . 349

Combining High and Low Frequencies in rTMS Antidepressive Treatment: Preliminary Results: **A. Conca, J. Di Pauli, W. Beraus, A. Hausmann, W. Peschina, H. Schneider, P. König and H. Hinterhuber** . . . 353

Evidence for a Relationship Between Daily Caffeine Consumption and Accuracy of Time Estimation: **M. McClellan Stine, R. J. O'Connor, B. R. Yatko, N. E. Grunberg and L. Cousino Klein** . . . 361

Acute Effects of Cigarettes in Non-deprived Smokers on Memory, Calculation and Executive Functions: **Y. Sakurai and I. Kanazawa** . . . 369

Short Report

Effects of Mirtazapine in Patients with Post-traumatic Stress Disorder in Korea: A Pilot Study: **W.-M. Bahk, C.-U. Pae, J. Tsoh, J-H. Chae, T-Y. Jun, C. Lee and K.-S. Kim** . . . 341

Case Report
Quinacrine-induced Psychiatric Disturbances in a Child with Common Variable Immunodeficiency and Chronic Giardiasis: **F. Genel, S. Erermis, G. Aksu, C. Ozturk and N. Kutukculer** 357

Book Review 375

Current Awareness 377

Issue No.8 December 2002

Reviews
Pharmacotherapy of Anxious Disorders: **M. Bourin and O. Lambert.** 383

Pharmacotherapy of Bipolar Disorder: The Role of Atypical Antipsychotics and Experimental Strategies: **G. S. Malhi and M. Berk** 407

Research Articles
Efficacy of Citalopram and Moclobemide in Patients with Social Phobia: Some Preliminary Findings: **M. Atmaca, M. Kuloglu, E. Tezcan and A. Unal** 401

The Effects of a Sedative Antihistamine, *d*-chlorpheniramine, on Visuomotor Spatial Discrimination and Regional Brain Activity as Measured by Positron Emission Tomography (PET): **H. Mochizuki, M. Tashiro, M. Tagawa, M. Kano, M. Itoh, N. Okamura, T. Watanabe and K. Yanai** 413

Platelet 5-HT_{2A}-receptor-mediated Induction of Aggregation is not Altered in Major Depression: **E. Gómez-Gil, C. Gastó, M. Díaz-Ricart, M. Carretero, M. Salamero, R. Catalán and G. Escolar** . . 419

Dextro-amphetamine Increases Phosphoinositol Cycle Activity in Volunteers: An MRS Study: **P. H. Silverstone, T. O'Donnell, M. Ulrich, S. Asghar and C. C. Hanstock** 425

Letter to the Editor
Elevation of Blood Pressure Induced by High-dose Milnacipran: **K. Yoshida, H. Higuchi, H. Takahashi and T. Shimizu** 431

Book Reviews 433

Current Awareness 435

Author Index 445

Keyword Index 447

Volume Contents iii